In the following years, many studies using different models of rodent experimental stroke (global forebrain ischemia, four-vessel occlusion, intraluminal pMCAO, pMCAO by electrocoagulation) confirmed the beneficial role of various A2AR antagonists—namely, CSC, CP 66,713, ZM 241385, SCH 58261—when being administered before ischemia [142, 143] or acutely after stroke [144–146]. The gene discussed is ADORA2A; the disease is Stroke.